Two recent reports compared romosozumab, an anti‑sclerostin monoclonal antibody, with parathyroid hormone (PTH 1–34) analogs for preventing osteoporotic fractures in women. Authors found romosozumab delivered superior reductions in fracture incidence in the studied cohorts and improved bone mineral density measures. The data, reported in peer‑reviewed outlets, reinforce romosozumab’s anabolic profile versus conventional anabolic PTH therapy and could influence treatment sequencing for high‑risk postmenopausal patients. Clinicians and payers will weigh fracture‑prevention benefits against known cardiovascular considerations in prescribing decisions; ongoing head‑to‑head and real‑world data will be decisive.